July 21, 2021
Pfizer Inc. has agreed to drop its four-year-old suit alleging Johnson & Johnson violated antitrust laws by coercing health insurers into not covering biosimilar versions of J&J's inflammatory disease biologic Remicade, Pfizer confirmed to Law360 on Wednesday.
August 10, 2018
Pfizer Inc. has credibly shown that Johnson & Johnson may have flouted antitrust laws by coercing health insurers into not covering biosimilar versions of biologic Remicade, a Pennsylvania federal judge said in a ruling released Friday.
November 29, 2017
Johnson & Johnson and its subsidiary Janssen Biotech Inc. urged a Pennsylvania federal court Tuesday to toss a suit brought by Pfizer Inc. alleging the companies used anti-competitive tactics to maintain the dominance of their biologic Remicade, saying Pfizer hasn't demonstrated the prices of its own biosimilar are competitive.
September 20, 2017
Pfizer Inc. can't break into the market with its biosimilar version of Johnson & Johnson's blockbuster biologic Remicade, as J&J and its subsidiary Janssen Biotech Inc. have been holding on to a monopoly through a multifaceted anti-competitive campaign, Pfizer told a Pennsylvania federal court Wednesday.